Skip to content

Released May 9, 2024, after the close

10-Q filed May 9, 2024, 39 days after period end · 0000950170-24-056869

Q1 2024 · 10-Q
Revenue$1.93M−96.7% vs Q1 2023+14.9% vs Q4 2023
Net Income-$48.00MN/M vs Q1 2023N/M vs Q4 2023
EPS Diluted-$0.47N/M vs Q1 2023no prior Q4 2023 on file
Operating Income-$51,068,000N/M
Operating Cash Flow-$33,350,000N/M
Free Cash Flowderived-$33,436,000N/M
Margins · derived
Operating margin-2652.9%−2604.4 pt vs Q1 2023
Net margin-2493.7%−2461.7 pt vs Q1 2023

What the release said

The release

Same quarter

MetricQ1 2024Q1 2023Q1 2022Q1 2021
Revenue$1.93M$58.98M$18.41M$11.14M
Net Income-$48.00M-$18.88M-$65.69M-$45.09M
EPS Diluted-$0.47-$0.19-$0.68-$0.48

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Fate Therapeutics Inc · CIK 1434316 · Engraved from SEC EDGAR